Harbour Capital Advisors LLC Has $1.62 Million Position in Stryker Corporation $SYK

Key Points

• Harbour Capital Advisors LLC increased its stake in Stryker Corporation by 41.5%, owning 4,139 shares valued at approximately $1.62 million as of the latest SEC filing.
• A significant transaction was reported where Director Ronda E. Stryker sold 200,000 shares for about $75.29 million, reducing her ownership by 5.84%.
• Stryker announced a quarterly dividend of $0.84 per share, with an upcoming payment date of October 31st, reflecting an annualized yield of 0.9%.

Harbour Capital Advisors LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 41.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,139 shares of the medical technology company's stock after buying an additional 1,213 shares during the period. Harbour Capital Advisors LLC's holdings in Stryker were worth $1,622,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Capital A Wealth Management LLC bought a new position in Stryker in the fourth quarter valued at about $26,000. Goodman Advisory Group LLC bought a new stake in Stryker during the 1st quarter valued at approximately $32,000. City Holding Co. raised its stake in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the period. Ransom Advisory Ltd purchased a new position in Stryker during the 1st quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Stryker during the 1st quarter valued at approximately $40,000. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

SYK stock traded down $5.45 during midday trading on Tuesday, hitting $372.78. 983,699 shares of the stock were exchanged, compared to its average volume of 1,393,045. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock's 50-day moving average price is $387.26 and its 200-day moving average price is $379.05. The stock has a market cap of $142.52 billion, a price-to-earnings ratio of 49.33, a PEG ratio of 2.71 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the prior year, the firm posted $2.81 EPS. The business's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker's dividend payout ratio is 44.50%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Truist Financial set a $415.00 target price on Stryker and gave the stock a "hold" rating in a report on Monday, August 4th. Wells Fargo & Company raised their price target on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They set a "neutral" rating and a $420.00 price target for the company. Needham & Company LLC raised their price target on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Fourteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.